Comparative Pharmacology
Head-to-head clinical analysis: TOFACITINIB versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOFACITINIB versus XELJANZ.
TOFACITINIB vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 and JAK3, thereby modulating the JAK-STAT signaling pathway to reduce cytokine production and immune cell activation.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
5 mg orally twice daily; extended-release formulation 11 mg orally once daily. For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. For ulcerative colitis, induction: 10 mg orally twice daily for 8 weeks, then maintenance 5 mg twice daily.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateTofacitinib + Digoxin
"Tofacitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTofacitinib + Bendroflumethiazide
"Tofacitinib may increase the bradycardic activities of Bendroflumethiazide."
Clinical Note
moderateTofacitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tofacitinib."
Clinical Note
moderateTofacitinib + Erythromycin
Terminal half-life approximately 3.3 hours in healthy volunteers. In patients with rheumatoid arthritis, effective half-life ~3-6 hours due to reversible binding to JAK enzymes. No significant accumulation at steady state.
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Primarily renal (70%) with 30% excreted unchanged in urine. Fecal elimination accounts for 20% (<1% unchanged). Minor biliary excretion.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category D/X
Category C
JAK Inhibitor
JAK Inhibitor
"The metabolism of Erythromycin can be decreased when combined with Tofacitinib."